Compare · DFTX vs LXRX

DFTX vs LXRX

Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Lexicon Pharmaceuticals Inc. (LXRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. DFTX focuses on Medicinal Chemicals and Botanical Products, while LXRX focuses on Biotechnology: Pharmaceutical Preparations.
  • DFTX is the larger of the two at $3.88B, about 5.7x LXRX ($681.2M).
  • DFTX has been more active in the news (9 items in the past 4 weeks vs 7 for LXRX).
  • DFTX has more recent analyst coverage (8 ratings vs 6 for LXRX).
MetricDFTXLXRX
Company
Definium Therapeutics Inc.
Lexicon Pharmaceuticals Inc.
Price
-
-
Market cap
$3.88B
$681.2M
1M return
-21.27%
-
1Y return
+141.13%
-
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
9
7
Recent ratings
8
6
LXRX

Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Latest DFTX

Latest LXRX